Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 44 out of 100. Costs and economics

Topic: Amyloid, tau and blood-test diagnosis

Plain-language summary

Background Multiple disease modifying treatment for Alzheimer's disease are currently in clinical development or have been recently approved for use. They have vastly different treatment properties but so far, little work has been done to quantify the impact of treatment properties on the treatment's value in terms of medical and social care costs and caregiver burden. Objectives This study aims to analyze how the mode of treatment administration, treatment frequency and duration, and monitoring requirements affect the value of disease modifying treatments. In order to isolate these effects, we compare five hypothetical disease modifying treatments with equal efficacy and safety: (1) chronic bi-weekly intravenous infusion, (2) chronic four-weekly intravenous infusion, (3) 52 weeks fixed duration four-weekly intravenous infusion, (4) chronic subcutaneous injections, and (5) chronic oral prescription on their direct medical costs, caregiver burden, and preservation of treatment value. Design Survey of Alzheimer's disease treatment clinics and retrospective data analysis. Setting United States. Measurements Direct medical cost and caregiver burden of treatment administration and monitoring compared to gross treatment benefit. Results Chronic bi-weekly infusion treatment had the highest direct medical cost ($45,208) and caregiver burden ($6,095), reducing the treatment value by 44%, while oral treatment with the lowest direct medical cost ($1,983) and caregiver burden ($457) reduced the treatment value by only 2%. Substantial caregiver burden was reported from the survey, with a reported average of 2.3 hours for an office visit and infusion, 44 minutes of round-trip travel time, and 78% of patients being accompanied by a caregiver for treatment. Conclusion Burden of chronic intravenous treatments exceed the gross medical and social care cost savings and value of caregiver benefit. The results suggest the need for less complex treatments that require fewer clinic visits to preserve the economic value of disease modifying treatments.

What this study adds

Evidence grade: Preliminary

Comparing five hypothetical disease-modifying treatments with equal efficacy and safety, chronic bi-weekly intravenous infusion had the highest direct medical cost and caregiver burden and reduced treatment value by 44%, while oral treatment reduced treatment value by only 2%. Reported effect size: Treatment value reduced by 44% (bi-weekly infusion) vs 2% (oral).

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Ozawa, T., Franguridi, G., & Mattke, S. (2024). Medical Costs and Caregiver Burden of Delivering Disease-Modifying Alzheimer's Treatments with Different Duration and Route of Administration. Journal of Prevention of Alzheimer's Disease. https://doi.org/10.14283/jpad.2024.81

Vancouver

Ozawa T, Franguridi G, Mattke S. Medical Costs and Caregiver Burden of Delivering Disease-Modifying Alzheimer's Treatments with Different Duration and Route of Administration. Journal of Prevention of Alzheimer's Disease. 2024. doi:10.14283/jpad.2024.81. PMID: 39350384.

BibTeX

@article{ozawa2024-39350384,
  author  = {Ozawa, T. and Franguridi, G. and Mattke, S.},
  title   = {{Medical Costs and Caregiver Burden of Delivering Disease-Modifying Alzheimer's Treatments with Different Duration and Route of Administration}},
  journal = {Journal of Prevention of Alzheimer's Disease},
  year    = {2024},
  doi     = {10.14283/jpad.2024.81},
  pmid    = {39350384},
  url     = {https://doi.org/10.14283/jpad.2024.81}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.

Key findings

Why it matters

Comparing five hypothetical disease-modifying treatments with equal efficacy and safety, chronic bi-weekly intravenous infusion had the highest direct medical cost and caregiver burden and reduced treatment value by 44%, while oral treatment reduced treatment value by only 2%. Because the treatments compared were hypothetical and assumed equally effective, this work addresses how administration route and monitoring affect cost and caregiver burden, not whether any treatment works.

Study details

Limitations

A stylised comparison of hypothetical treatments rather than actual products, ignoring differences in effect size, adverse events and eligibility; discontinuation rates were disregarded; caregiver burden came from a survey of clinic staff rather than time-use data; and caregiver time for injections and prescription refills was not counted, possibly underestimating subcutaneous and oral burden.

How this study scored 44/100
How this study's score is builtJournal tier 7 of 10; Journal's citation record 0 of 4; Study design 3 of 12; Strength of evidence 2 of 5; Peer-review validation 10 of 10; How recent 4 of 5; Sample size 0 of 4; Effect reported 2 of 3; Studied in people 0 of 3; Randomized / blinded 0 of 2; Times cited 2 of 7; Citations per year 2 of 5; Impact for its field and year 3 of 6; Cited by studies here 0 of 6; Still being cited 1 of 4; Senior author's track record 3 of 4; Institution's track record 2 of 3; Multicenter collaboration 0 of 3; Indexed in PubMed 2 of 2; Free to read left out, no data. 43 of the 98 points it could be judged on, which is 44 of 100. Total 44 of 100.43 of the 98 points we could judge = 44 of 100

Published in a peer-reviewed journal, and it is a computer model rather than new measurements. Scored zero for sample size, studied in people and randomized / blinded because the record does not state it. We have no data on free to read, so that was left out: it earned 43 of the 98 points we could judge it on, which is 44 out of 100.

ComponentPointsWhy
Journal tier 7 / 10 Tier 3 — peer-reviewed journal (Journal of Prevention of Alzheimer's Disease)
Journal's citation record 0 / 4 The Journal of Prevention of Alzheimer s Disease: journal h-index 63 (OpenAlex, 2026-10-29)
Study design 3 / 12 A computer model rather than new measurements
Strength of evidence 2 / 5 Rated “preliminary” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 4 / 5 2024 — within 3 year(s) of the newest study here
Sample size 0 / 4 Participant count not stated — scores zero (not stated in the record — scored 0)
Effect reported 2 / 3 Effect reported as a number, without an interval or test
Studied in people 0 / 3 Not stated whether this was studied in people — scores zero (not stated in the record — scored 0)
Randomized / blinded 0 / 2 No randomization or blinding stated — scores zero (not stated in the record — scored 0)
Times cited 2 / 7 Cited 13 times (OpenAlex, 2026-10-10)
Citations per year 2 / 5 3.2 citations a year over 4 year(s) since 2024
Impact for its field and year 3 / 6 Cited 3.1× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 0 / 6 No other study in this library cites it
Still being cited 1 / 4 Cited 13 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 3 / 4 Last-listed author Soeren Mattke: h-index 50 (OpenAlex, whole career)
Institution's track record 2 / 3 University of Southern California: institution h-index 1,521 (OpenAlex)
Multicenter collaboration 0 / 3 OpenAlex lists 1 institution(s) in 1 country — scores zero (affiliation lists can be incomplete)
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 39350384)
Free to read — / 2 Access not recorded — left out of this score
Points 43 / 98 Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 43 of the 98 points we could judge it on is 44 out of 100.
Total 44 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — PubMed Central lists this copy as free to read: the link above (checked 10 Oct 2026).

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here.

Related studies in Costs and economics from nearby years

Also in Costs and economics

21 studies in the library are filed under Costs and economics with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Costs and economics hub.

Similar studies

More on Costs and economics

See all studies in Costs and economics →